Regulatory · source year

2012 regulatory records

22 selected, source-linked regulatory records dated 2012. This is selective source coverage, not a complete timeline.

Dated records

22 selected records.

Peptide profiles

16 connected profiles.

Cited sources

22 distinct public records.

Cited chronology

Dated source records

All record types in 2012 →

December 2012

3 records

Desmopressin

Federal Register notice 2012-30308

The Federal Register published notice 2012-30308, attributed to FDA and its parent HHS department, on 2012-12-17. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

Source: Federal Register via GovInfo ↗

→

October 2012

2 records

Triptorelin

Federal Register rule 2012-25989

The Federal Register published rule 2012-25989, attributed to FDA and its parent HHS department, on 2012-10-23. Its official title is “New Animal Drugs; Approvals; Changes of Sponsor; Change of Sponsor's Name; Change of Sponsor's Address; Alfaxalone; Ivermectin and Clorsulon; Narasin; Triptorelin,” and PeptideScanner's exact reviewed identity mapping connects the document to Triptorelin.

Source: Federal Register via GovInfo ↗

→

Pasireotide

Federal Register notice 2012-25483

The Federal Register published notice 2012-25483, attributed to FDA and its parent HHS department, on 2012-10-17. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Pasireotide.

Source: Federal Register via GovInfo ↗

→

September 2012

4 records

Calcitonin salmon

Federal Register notice 2012-22658

The Federal Register published notice 2012-22658, attributed to FDA and its parent HHS department, on 2012-09-14. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.

Source: Federal Register via GovInfo ↗

→

Oxytocin

Federal Register notice 2012-22195

The Federal Register published notice 2012-22195, attributed to FDA and its parent HHS department, on 2012-09-10. Its official title is “Withdrawal of Approval of New Animal Drug Applications; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

Source: Federal Register via GovInfo ↗

→

Oxytocin

Federal Register rule 2012-22196

The Federal Register published rule 2012-22196, attributed to FDA and its parent HHS department, on 2012-09-10. Its official title is “New Animal Drugs; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

Source: Federal Register via GovInfo ↗

→

August 2012

2 records

Teduglutide

Federal Register notice 2012-20612

The Federal Register published notice 2012-20612, attributed to FDA and its parent HHS department, on 2012-08-22. Its official title is “Gastrointestinal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Teduglutide.

Source: Federal Register via GovInfo ↗

→

July 2012

1 record

May 2012

3 records

Vasopressin

Federal Register notice 2012-12040

The Federal Register published notice 2012-12040, attributed to FDA and its parent HHS department, on 2012-05-18. Its official title is “Determination That PITRESSIN TANNATE IN OIL (Vasopressin Tannate) Injection, 5 Pressor Units/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.

Source: Federal Register via GovInfo ↗

→

Tesamorelin

Federal Register notice 2012-10808

The Federal Register published notice 2012-10808, attributed to FDA and its parent HHS department, on 2012-05-04. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; EGRIFTA,” and PeptideScanner's exact reviewed identity mapping connects the document to Tesamorelin.

Source: Federal Register via GovInfo ↗

→

Liraglutide

Federal Register notice 2012-10517

The Federal Register published notice 2012-10517, attributed to FDA and its parent HHS department, on 2012-05-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Victoza,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.

Source: Federal Register via GovInfo ↗

→

April 2012

2 records

Carfilzomib

Federal Register notice 2012-10154

The Federal Register published notice 2012-10154, attributed to FDA and its parent HHS department, on 2012-04-27. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib.

Source: Federal Register via GovInfo ↗

→

March 2012

2 records

Secretin

Federal Register notice 2012-6971

The Federal Register published notice 2012-6971, attributed to FDA and its parent HHS department, on 2012-03-23. Its official title is “Gastrointestinal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Secretin.

Source: Federal Register via GovInfo ↗

→

February 2012

1 record

Desmopressin

Federal Register notice 2012-4037

The Federal Register published notice 2012-4037, attributed to FDA and its parent HHS department, on 2012-02-22. Its official title is “Final Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

Source: Federal Register via GovInfo ↗

→

January 2012

2 records

Leuprolide + 1 more

Federal Register notice 2012-1433

The Federal Register published notice 2012-1433, attributed to FDA and its parent HHS department, on 2012-01-25. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.

Source: Federal Register via GovInfo ↗

→